Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer.
adjuvant chemotherapy
anaplastic thyroid carcinoma
combined modality therapy
head and neck cancer
radiation therapy
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
06
2019
revised:
02
01
2020
accepted:
10
01
2020
pubmed:
6
2
2020
medline:
22
6
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
EBRT in resected, nonmetastatic anaplastic thyroid cancer (ATC) remains undefined. We evaluated patterns/outcomes with EBRT and chemotherapy in this setting. This retrospective analysis included patients identified from the National Cancer Database with nonmetastatic ATC from 2004 to 2014 who underwent non-palliative resection. Our analysis included 496 patients, including 375 who underwent adjuvant EBRT (among whom 198 received concurrent chemotherapy). The median age was 68 years. On MVA, EBRT was associated with sex (OR 0.5, 95% CI 0.3-0.8, P = .002) and income (OR 2.2, 95% CI 1.4-3.3, P < .001). EBRT was associated with longer OS on UVA (12.3 vs 9.1 months, P = .004) and MVA (HR 0.7 [CI 0.6-0.9], P = .004). Concurrent chemoradiation was associated with longer OS on UVA (14.0 vs 9.1 months, P = .003) and MVA (HR 0.6 [CI 0.5-0.8], P < .001). Adjuvant EBRT is associated with longer OS in resected, nonmetastatic ATC, with additional improved survival with concurrent chemotherapy.
Sections du résumé
BACKGROUND
EBRT in resected, nonmetastatic anaplastic thyroid cancer (ATC) remains undefined. We evaluated patterns/outcomes with EBRT and chemotherapy in this setting.
METHODS
This retrospective analysis included patients identified from the National Cancer Database with nonmetastatic ATC from 2004 to 2014 who underwent non-palliative resection.
RESULTS
Our analysis included 496 patients, including 375 who underwent adjuvant EBRT (among whom 198 received concurrent chemotherapy). The median age was 68 years. On MVA, EBRT was associated with sex (OR 0.5, 95% CI 0.3-0.8, P = .002) and income (OR 2.2, 95% CI 1.4-3.3, P < .001). EBRT was associated with longer OS on UVA (12.3 vs 9.1 months, P = .004) and MVA (HR 0.7 [CI 0.6-0.9], P = .004). Concurrent chemoradiation was associated with longer OS on UVA (14.0 vs 9.1 months, P = .003) and MVA (HR 0.6 [CI 0.5-0.8], P < .001).
CONCLUSION
Adjuvant EBRT is associated with longer OS in resected, nonmetastatic ATC, with additional improved survival with concurrent chemotherapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1044Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Smallridge RC, Abate EG. Anaplastic thyroid carcinoma: prognosis. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer. New York, NY: Springer; 2006:953-956.
Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-1335.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (Version 1.2018). https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed June 15, 2018.
Smallridge RC, Ain KB, Asa SL. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. American thyroid association anaplastic thyroid cancer guidelines taskforce. Thyroid. 2012;22(11):1104-1139.
American College of Surgeons. National Cancer Database. https://www.facs.org/quality-programs/cancer/ncdb. Accessed March 23, 2018, 2018.
Park HS, Gross CP, Makarov DV, Yu JB. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1365-1373.
Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554-568.
Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remich SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.
Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes form the National Cancer Data Base. Cancer. 2017;123(9):1653-1661.
Glaser S, Mandish S, Gill B, et al. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38(S1):E2083-E2090.
Wan Y, Tsang R, Asa S, Dickson B, Arenovich R, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer. 2006;107(8):1786-1792.
McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130(6):1028-1034.
Vulpe H, Kwan JYY, McNiven A, et al. Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy. Curr Oncol. 2017;24(3):e226-e232.
So K, Smith RE, Davis SR. Radiotherapy in anaplastic thyroid carcinoma: an Australian experience. J Med Imaging Radiat Oncol. 2017;61(2):279-287.
Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid Cancer. Endocrinol Metab Clin N Am. 2008;37(2):525-538.
Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol. 2014;9(1):90.
Shinohara S, Kikuchi M, Naito Y, et al. Successful treatment of locally advanced anaplastic thyroid carcinoma by chemotherapy and hyperfractionated radiotherapy. Auris Nasus Larynx. 2009;36(6):729-732.
Liu AH, Juan LY, Yang AH, Chen HS, Lin HD. Anaplastic thyroid cancer with uncommon long-term survival. J Chin Med Assoc. 2006;69(10):489-491.
De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137-1143.
Dandekar P, Harmer C, Barbachano Y, et al. Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009;74(2):518-521.
Sher DJ, Neville BA, Chen AB, et al. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011;81:e197-e206.
Park HS, Decker RH. Disparities in radiation therapy delivery: current evidence and future directions in head and neck cancer. Head Neck. 2016;1:5.
Murphy CT, Galloway TJ, Handorf EA, et al. Survival impact of increasing time to treatment initiation for patients with head and neck Cancer in the United States. J Clin Oncol. 2016;34:169-178.
Yu JB, Soulos PR, Sharma R, et al. Patterns of care and outcomes associated with intensity-modulated radiation therapy versus conventional radiation therapy for older patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:e101-e107.
Beadle BM, Liao KP, Elting LS, et al. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer. 2014;120:702-710.
Goulart BH, Reyes CM, Fedorenko CR, et al. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract. 2013;9:42-50.
Roche AM, Fedewa SA, Shi LL, Chen AY. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. Cancer. 2018;124(8):1780-1790.
Shah SA, Adam MA, Thomas SM, et al. Racial disparities in differentiated thyroid Cancer: have we bridged the gap? Thyroid. 2017 Jun;27(6):762-772.
Shugarman LR, Sorbero MES, Tian H, Jain AK, Ashwood JS. An exploration of urban and rural differences in lung cancer survival among medicare beneficiaries. Am J Public Health. 2008;98(7):1280-1287.
Martinez SR, Shah DR, Tseng WH, Canter RJ, Bold RJ. Rural-urban disparities in use of post-lumpectomy radiation. Med Oncol. 2012 Dec;29(5):3250-3257.
Tyldesley S, McGahan C. Utilisation of radiotherapy in rural and urban areas in British Columbia compared with evidence-based estimates of radiotherapy needs for patients with breast, prostate and lung Cancer. Clin Oncol (R Coll Radiol). 2010;22(7):526-532.
Schootman M, Aft R. Rural-urban differences in radiation therapy for ductal carcinoma in-situ of the breast. Breast Cancer Res Treat. 2001 Jul;68(2):117-125.
Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011 Jan;21(1):25-30.
Phan AV. Molecular signatures of radiation response in human-derived anaplastic thyroid cancer and poorly differentiated thyroid cancer. Int J Radiat Oncol Biol Phys. 2018;100(5):1381-1382.
Robb RN, Yang L, Williams T. Vemurafenib selectively radiosensitizes BRAF V600E mutant papillary and anaplastic thyroid carcinoma cells. Presented at: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC.
Cabanillas ME, Zafereo M, Gunn B, Ferrarotto R. Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract. 2016;12(6):511-518.